← Encyclopedia

Sub-perceptual dosing.

Example: Open-label reports are enthusiastic, but the rigorous, placebo-controlled evidence hasn't followed — a 2026 microdosed-LSD depression trial we covered looked strong in open-label testing, then failed to beat an active placebo once a real control arm was added. Worth remembering when the enthusiasm and the trial design don't match.